Histopathology of Hodgkin's lymphoma

Cancer Journal

Volumn 15, Issue 2, 2009, Pages 129-137

  Eberle, Franziska C ^a   Mani, Haresh ^a   Jaffe, Elaine S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Classical Hodgkin's lymphoma; Epidemiology; Epstein Barr virus; Gray zone lymphomas; Immunophenotyping; Nodular lymphocyte predominant Hodgkin's lymphoma; Pathology; Primary mediastinal large B cell lymphoma

Indexed keywords

B CELL LYMPHOMA; CANCER CLASSIFICATION; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; MEDIASTINUM DISEASE; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW;

HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; LYMPHOMA, B-CELL;

EID: 68049137657     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31819e31cf     Document Type: Review

References (118)

1. Hodgkin's T. On some morbid experiences of the absorbent glands and spleen. Medicochirurgic Trans. 1832;17:68-97.
2. Wilks S. Cases of enlargement of the lymphatic glands and spleen (or Hodgkin's disease). Guys Hosp Rep. 1865;11:56-67.
3. Reed DM. On the pathological changes in Hodgkin's disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902; 1902:133-196.
4. Dawson PJ. Whatever happened to Dorothy Reed? Ann Diagn Pathol. 2003;7:195-203.
5. Gall EA, Mallory TB. Malignant lymphoma: a clinico-pathologic survey of 618 cases. Am J Pathol. 1942;18:381-429.
6. Jackson H, Parker F. Hodgkin's disease. II. Pathology. N Engl J Med. 1944;231:35-44.
7. Lukes R, Butler J, Hicks E. Natural history of Hodgkin's disease as related to its patholgical picture. Cancer. 1966;19:317-344.
8. Lukes RJ, Craver LF, Hall TC, et al. Report of the nomenclature committee. Cancer Res. 1966;26:1311.
9. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
10. Jaffe ES, Harris NL, Stein H, et al. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
11. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
12. Schmid C, Pan L, Diss T, et al. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol. 1991;139:701-707.
13. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin's disease: Hodgkin's and Reed Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA. 1994;91:1092-1096.
14. Mason D, Banks P, Chan J, et al. Nodular lymphocyte predominance Hodgkin's disease: a distinct clinico-pathological entity. Am J Surg Pathol. 1994;18:528-530.
15. Levy A, Armon Y, Gopas J, et al. Is classicalal Hodgkin's disease indeed a single entity? Leuk Lymphoma. 2002;43:1813-1818.
16. Glaser SL, Clarke CA, Darrow LA. Hodgkin's disease etiology and novel viruses: clues from groups exposed to blood products. Int J Cancer. 2003;104:796-797.
17. Jarrett RF, MacKenzie J. Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease. Semin Hematol. 1999;36:260-269.
18. Armstrong AA, Alexander FE, Cartwright R, et al. Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis. Leukemia. 1998;12:1272-1276.
19. Delecluse HJ, Marafioti T, Hummel M, et al. Disappearance of the Epstein-Barr virus in a relapse of Hodgkin's disease. J Pathol. 1997;182:475-479.
20. Clavel J, Steliarova-Foucher E, Berger C, et al. Hodgkin's disease incidence and survival in European children and adolescents (1978-1997): report from the Automated Cancer Information System project. Eur J Cancer. 2006;42: 2037-2049.
21. Clarke CA, Glaser SL, Keegan TH, et al. Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev. 2005;14:1441-1447.
22. Henderson BE, Dworsky R, Pike MC, et al. Risk factors for nodular sclerosis and other types of Hodgkin's disease. Cancer Res. 1979;39:4507-4511.
23. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005;23:5052-5060.
24. Keegan TH, Glaser SL, Clarke CA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol. 2005;23:7604-7613.
25. Cozen W, Katz J, Mack TM. Risk patterns of Hodgkin's disease in Los Angeles vary by cell type. Cancer Epidemiol Biomarkers Prev. 1992;1:261-268.
26. Cozen W, Cerhan JR, Martinez-Maza O, et al. The effect of atopy, childhood crowding, and other immune-related factors on non-Hodgkin's lymphoma risk. Cancer Causes Control. 2007;18:821-831.
27. Devilard E, Bertucci F, Trempat P, et al. Gene expression profiling defines molecular subtypes of classicalal Hodgkin's disease. Oncogene. 2002;21: 3095-3102.
28. Colby T, Hoppe R, Warnke R. Hodgkin's disease: a clinicopathologic study of 659 cases. Cancer. 1981;49:1848-1858.
29. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-1636.
30. Ohshima K, Akaiwa M, Umeshita R, et al. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology. 2001;38:368-375.
31. Newcom SR, Kadin ME, Ansari AA. Production of transforming growth factor-beta activity by Ki-1 positive lymphoma cells and analysis of its role in the regulation of Ki-1 positive lymphoma growth. Am J Pathol. 1988; 131:569-577.
32. Pituch-Noworolska A, Drabik G, Kacinska E, et al. Lymphocyte populations in lymph nodes in different histological types of Hodgkin's disease in children. Acta Haematol. 2004;112:129-135.
33. Kanzler H, Kuppers R, Hansmann ML, et al. Hodgkin's and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996; 184:1495-1505.
34. Marafioti T, Hummel M, Foss HD, et al. Hodgkin's and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95:1443-1450.
35. Strickler J, Michie S, Warnke R, et al. The "syncytial variant" of nodular sclerosing Hodgkin's disease. Am J Surg Pathol. 1986;10:470-477.
36. Ben-Yehuda-Salz D, Ben-Yehuda A, Polliack A, et al. Syncytial variant of nodular sclerosing Hodgkin's disease. A new clinicopathologic entity. Cancer. 1990;65:1167-1172.
37. DeVita VT Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980;92: 587-595.
38. Johnson RE, Zimbler H, Berard CW, et al. Radiotherapy results for nodular sclerosing Hodgkin's disease after clinical staging. Cancer. 1977;39:1439-1444.
39. Bennett MH, MacLennan KA, Easterling MJ, et al. The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22). Clin Radiol. 1983;34:497-501.
40. MacLennan K, Bennett M, Tu A, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. Cancer. 1989;64:1686-1693.
41. Hess J, Bodis S, Pinkus G, et al. Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients. Cancer. 1994;74:708-714.
42. Ferry JA, Linggood RM, Convery KM, et al. Hodgkin's disease, nodular sclerosis type. Implications of histologic subclassification. Cancer. 1993;71: 457-463.
43. Harris NL. Hodgkin's lymphomas: classification, diagnosis, and grading. Semin Hematol. 1999;36:220-232.
44. von Wasielewski S, Franklin J, Fischer R, et al. Nodular sclerosing Hodgkin's disease: new grading predicts prognosis in intermediate and advanced stages. Blood. 2003;101:4063-4069.
45. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin's lymphoma. J Exp Med. 2003;198:851-862.
46. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classicalal Hodgkin's lymphoma. Blood. 2003;102:3871-3879.
47. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classical Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29:1411-1421.
48. Kanavaros P, Gaulard P, Charlotte F, et al. Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B-cell lymphomas. Am J Pathol. 1995;146:735-741.
49. Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002;15:1172-1180.
50. Hsi ED, Sup SJ, Alemany C, et al. MAL is expressed in a subset of Hodgkin's lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol. 2006;125:776-782.
51. Pileri S, Bocchia M, Baroni C, et al. Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinicopathologic study of 69 cases. Br J Haematol. 1994;86:513-523.
52. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol. 2001;14:219-228.
53. Zinzani PL, Martelli M, Magagnoli M, et al. Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood. 1998;92:790-794.
54. Cazals-Hatem D, Andre M, Mounier N, et al. Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study. Am J Surg Pathol. 2001;25:297-306.
55. Dunleavy D, Pittaluga S, Grant N, et al. Gray zone lymphomas: clinical and histological characteristics and treatment with dose-adjusted EPOCH-R. Blood. 2008;112:1228.
56. Zarate-Osorno A, Roman LN, Kingma DW, et al. Hodgkin's disease in Mexico. Prevalence of Epstein-Barr virus sequences and correlations with histologic subtype. Cancer. 1995;75:1360-1366.
57. Ambinder RF, Browning PJ, Lorenzana I, et al. Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. Blood. 1993;81:462-467.
58. Siddiqui N, Ayub B, Badar F, et al. Hodgkin's lymphoma in Pakistan: a clinico-epidemiological study of 658 cases at a cancer center in Lahore. Asian Pac J Cancer Prev. 2006;7:651-655.
59. Clarke CA, Glaser SL. Epidemiologic trends in HIV-associated lymphomas. Curr Opin Oncol. 2001;13:354-359.
60. Glaser SL, Clarke CA, Gulley ML, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin's lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer. 2003;98:300-309.
61. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin's lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108:3786-3791.
62. Stein L, Urban MI, O'Connell D, et al. The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004. Int J Cancer. 2008;122:2260-2265.
63. Neiman RS, Rosen PJ, Lukes RJ. Lymphocyte-depletion Hodgkin's disease. A clinicopathological entity. N Engl J Med. 1973;288:751-755.
64. Axtell L, Myers M, Thomas L, et al. Prognostic indicators in Hodgkin's disease. Cancer. 1972;29:1481-1488.
65. Kant JA, Hubbard SM, Longo DL, et al. The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease. J Clin Oncol. 1986;4:284-294.
66. Allemani C, Sant M, De Angelis R, et al. Hodgkin's disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer. 2006;107:352-360.
67. MacMahon B. Epidemiology of Hodgkin's disease. Cancer Res. 1966;26: 1189-1201.
68. Kadin ME, Donaldson SS, Dorfman RF. Isolated granulomas in Hodgkin's disease. N Engl J Med. 1970;283:859-861.
69. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26:1063-1083.
70. Garcia JF, Mollejo M, Fraga M, et al. Large B-cell lymphoma with Hodgkin's features. Histopathology. 2005;47:101-110.
71. Oyama T, Ichimura K, Suzuki R, et al. Senile EBV + B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol. 2003;27:16-26.
72. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110:972-978.
73. Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin's disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin's disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96:1889-1899.
74. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte- predominant Hodgkin's disease and lymphocyte-rich classicalal Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999;17:776-783.
75. Shimabukuro V. Lymphocyte-rich classicalal Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials (vol 23, pg 5739, 2005). J Clin Oncol. 2006;24:2220-12220
76. Brauninger A. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classicalal Hodgkin's lymphoma in relation to tumor cells of classicalal and lymphocyte-predominance Hodgkin's lymphoma. Cancer Res. 2003;63:1644-1651.
77. Ashton-Key M, Thorpe PA, Allen JP, et al. Follicular Hodgkin's disease. Am J Surg Pathol. 1995;19:1294-1299.
78. Lennert K, Mohri N. Histologische Klassifizierung and Vorkommen des M. Hodgkin's Internist. 1974;15:57-65.
79. Chang K-C, Khen NT, Jones D, et al. Epstein-Barr virus is associated with all histological subtypes of Hodgkin's lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype. Hum Pathol. 2005;36:747-755.
80. Regula D, Hoppe R, Weiss L. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med. 1988;318:214-219.
81. Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27:1346-1356.
82. Poppema S, Kaiserling E, Lennert K. Nodular paragranuloma and progressively transformed germinal centers: ultrastructural and immunohistochemical findings. Virchows Arch [B]. 1979;31:211-225.
83. Ferry JA, Zukerberg LR, Harris NL. Florid progressive transformation of germinal centers. A syndrome affecting young men, without early progression to nodular lymphocyte predominance Hodgkin's disease. Am J Surg Pathol. 1992;16:252-258.
84. Sundeen JT, Cossman J, Jaffe ES. Lymphocyte predominant Hodgkin's disease, nodular subtype with coexistent "large cell lymphoma." Histological progression or composite malignancy? Am J Surg Pathol. 1988;12:599-606.
85. Hansmann M, Stein H, Fellbaum C, et al. Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. Hum Pathol. 1989;20:1169-1175.
86. Huang JZ, Weisenburger DD, Vose JM, et al. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin's lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma. 2004;45:1551-1557.
87. Greiner TC, Gascoyne RD, Anderson ME, et al. Nodular lymphocyte- predominant Hodgkin's disease associated with large-cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood. 1996;88:657-666.
88. Wickert RS, Weisenburger DD, Tierens A, et al. Clonal relationship between lymphocytic predominance Hodgkin's disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood. 1995;86:2312-2320.
89. Rudiger T, Gascoyne RD, Jaffe ES, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol. 2002;13:44-51.
90. Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte predominant Hodgkin's lymphoma with nodules resembling T-cell/histiocyte rich B-cell lymphoma: differential diagnosis between nodular lymphocyte predominant Hodgkin's lymphoma and T-cell/histiocyte rich B-cell lymphoma. Blood. 2003;24:24.
91. Stein H, Gerdes J, Schwab U, et al. Identification of Hodgkin's and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer. 1982;30:445-459.
92. Goldbrunner R, Warmuth-Metz M, Tonn JC, et al. Primary Ki-1-positive T-cell lymphoma of the brain-an aggressive subtype of lymphoma: case report and review of the literature. Surg Neurol. 1996;46:37-41.
93. Hsu SM, Yang K, Jaffe ES. Phenotypic expression of Hodgkin's and Reed-Sternberg cells in Hodgkin's disease. Am J Pathol. 1985;118:209-217.
94. Chittal S, Caveriviere P, Schwarting R, et al. Monoclonal antibodies in the diagnosis of Hodgkin's disease. The search for a rational panel. Am J Surg Pathol. 1988;12:9-21.
95. Tzankov A, Krugmann J, Fend F, et al. Prognostic significance of CD20 expression in classicalal Hodgkin's lymphoma: a clinicopathological study of 119 cases. Clin Cancer Res. 2003;9:1381-1386.
96. Schwering I, Brauninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin's and Reed-Sternberg cells of Hodgkin's lymphoma. Blood. 2003;101:1505-1512.
97. Weiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med. 1989;320:502-506.
98. Gandhi MK, Moll G, Smith C, et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classical Hodgkin's lymphoma. Blood. 2007;110:1326-1329.
99. Stein H, Hansmann M, Lennert K, et al. Reed-Sternberg and Hodgkin's cells in lymphocyte-predominant Hodgkin's disease of nodular subtype contain J chain. Am J Clin Pathol. 1986;86:292-297.
100. Schmid C, Sargent C, Isaacson P. L and H cells of nodular lymphocyte predominant Hodgkin's disease show immunoglobulin light-chain restriction. Am J Pathol. 1991;139:1281-1289.
101. Prakash S, Fountaine T, Raffeld M, et al. IgD Positive L&H Cells Identify a Unique Subset of Nodular Lymphocyte Predominant Hodgkin's Lymphoma. Am J Surg Pathol. 2006;30:585-592.
102. Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classicalal Hodgkin's disease provides further evidence for its B-cell origin. Blood. 1999;94: 3108-3113.
103. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB. 1/OBF. 1 and Oct2 in classicalal Hodgkin's disease but not in lymphocyte predominant Hodgkin's disease correlates with immunoglobulin transcription. Blood. 2001;97:496-501.
104. Marafioti T, Mancini C, Ascani S, et al. Leukocyte-specific phosphoprotein-1 and PU. 1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease. Haematologica. 2004;89:957-964.
105. von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol. 1997;151: 1123-1130.
106. Portlock CS, Donnelly GB, Qin J, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classicalal Hodgkin's disease. Br J Haematol. 2004;125:701-708.
107. Tzankov A, Bourgau C, Kaiser A, et al. Rare expression of T-cell markers in classicalal Hodgkin's lymphoma. Mod Pathol. 2005;18:1542-1549.
108. Kuppers R, Brauninger A. Reprogramming of the tumour B-cell phenotype in Hodgkin's lymphoma. Trends Immunol. 2006;27:203-205.
109. Muschen M, Rajewsky K, Brauninger A, et al. Rare occurrence of classicalal Hodgkin's disease as a T cell lymphoma. J Exp Med. 2000;191:387-394.
110. Seitz V, Hummel M, Marafioti T, et al. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classical Hodgkin's disease. Blood. 2000;95:3020-3024.
111. Barry TS, Jaffe ES, Sorbara L, et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol. 2003;27:1513-1522.
112. Davis T, Morton C, Miller-Cassman R, et al. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med. 1992;326:1115-1122.
113. Timmens W, Visser L, Poppema S. Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma. Lab Invest. 1986;54: 457-461.
114. Kamel OW, Gelb AB, Shibuya RB, et al. Leu 7 (CD57) reactivity distinguishes nodular lymphocyte predominance Hodgkin's disease from nodular sclerosing Hodgkin's disease, T-cell-rich B-cell lymphoma and follicular lymphoma. Am J Pathol. 1993;142:541-546.
115. Nam-Cha SH, Roncador G, Sanchez-Verde L, et al. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin's lymphoma. Am J Surg Pathol. 2008;32:1252-1257.
116. Cossman J, Messineo C, Bagg A. Reed-Sternberg cell: survival in a hostile sea. Lab Invest. 1998;78:229-235.
117. Ishida T, Ishii T, Inagaki A, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin's lymphoma fosters immune privilege. Cancer Res. 2006;66:5716-5722.
118. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin's lymphoma. Blood. 2004;103:1755-1762.